Greenwich LifeSciences expands FLAMINGO-01 clinical trial into Europe
Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Greenwich LifeSciences announces activation of Phase 3 trial in Poland
Greenwich LifeSciences (GLSI) announced the activation of clinical sites in Poland in tis Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Bullish Greenwich LifeSciences Insiders Loaded Up On US$3.39m Of Stock
In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) stock, indicating that insiders' optimism about the company's prospects ...
Nasdaq2d
Greenwich LifeSciences Expands FLAMINGO-01 Trial With Polish Collaboration
(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, on Monday announced the activation of multiple clinical sites in Poland for its Phase III clinical ...
Mena FN2d
Greenwich Lifesciences Announces Activation Of Flamingo-01 In Poland
(MENAFN- GlobeNewsWire - Nasdaq) STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage ...